Table 3

Disease subtypes, molecular/cytogenetic data, and CalcuSyn synergy of ex vivo–cultured patient samples

Patient no.FAB subtype/CML phaseCytogenetics/mutationBlast, %CI at 380nM MKAraC for maximum synergy (CI) at 380nM MK, nM
AML 1 M6   * * 
AML 2 M4  78 * * 
AML 4 M5   * * 
AML 6 M2  74 * * 
AML 7  Inv3, 5q−, −7 60-70 0.41 80 
AML 8 AMML Diploid 60 0.22 14 
AML 9 M5 11q23  0.43 120 
MDS 10 Evolving to AML Diploid 10-15 0.24 
MDS 11  Diploid 0.45 80 
CML 12 CP (> 70% Ph+t(9;22) 0.42 1100 
CML 13 AP t(9;22) 0.21 40 
CML 14 BC, refractory 7q−, inv3 21 * * 
CML 3 BC t(9;22), (T315I * * 
CML 5 AP t(9;22), (F359V * * 
Patient no.FAB subtype/CML phaseCytogenetics/mutationBlast, %CI at 380nM MKAraC for maximum synergy (CI) at 380nM MK, nM
AML 1 M6   * * 
AML 2 M4  78 * * 
AML 4 M5   * * 
AML 6 M2  74 * * 
AML 7  Inv3, 5q−, −7 60-70 0.41 80 
AML 8 AMML Diploid 60 0.22 14 
AML 9 M5 11q23  0.43 120 
MDS 10 Evolving to AML Diploid 10-15 0.24 
MDS 11  Diploid 0.45 80 
CML 12 CP (> 70% Ph+t(9;22) 0.42 1100 
CML 13 AP t(9;22) 0.21 40 
CML 14 BC, refractory 7q−, inv3 21 * * 
CML 3 BC t(9;22), (T315I * * 
CML 5 AP t(9;22), (F359V * * 

Samples span a wide range of AML subtypes by French-American-British and cytogenetic classification. CML samples encompass one patient with high Ph+ disease burden and samples from accelerated phase (AP) and blast crisis (BC) CML, some of which harbored BCR-ABL mutations. The CI values at 380nM MK1775, for which the strongest synergy was observed, are listed with the corresponding Ara-C concentrations. Samples are derived from BM.

*

Insufficient sample material was available for CalcuSyn analysis.

190nM MK1775.

Close Modal

or Create an Account

Close Modal
Close Modal